Skip to main content

Table 4 Time-to-onset analysis of bisphosphonates stratified by formulations and dosages

From: Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events

Dosage form

Drug name

Case (number for analysis)

Median of time-to-onset (day)

Lower quartile of time-to-onset (day)

Upper quartile of time-to-onset (day)

Scale parameter: α

Shape parameter: β

α

(95 % CI)

β

(95 % CI)

Intravenous

Pamidronate (30 − 45 mg)

44

(35)

844

658

1,199

775.6

(641.8 − 928.9)

1.98

(1.49 − 2.53)

 

Pamidronate (90 mg)

66

(48)

783

532

1,041

889.5

(706.1 − 1112.6)

1.35

(1.09 − 1.63)

 

Zoredronate (4 mg)

494

(355)

488

290

811

634.1

(587.7 − 683.4)

1.46

(1.34 − 1.59)

Oral

Arendronate (5 mg)

155

(72)

1,263

757

1,951

1450.5

(1258.1 − 1664.5)

1.77

(1.46 − 2.12)

 

Arendronate (35 mg)

202

(102)

680

309

1,106

804.9

(663.0 − 972.3)

1.08

(0.91 − 1.25)

 

Risedronate (2.5 mg)

73

(39)

1,081

495

1,706

1288.6

(1008.4 − 1634.3)

1.41

(1.06 − 1.82)

 

Risedronate (17.5 mg)

35

(14)

112

33

407

295.0

(129.5 − 636.9)

0.82

(0.96 − 1.23)